⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Eluxadoline

الوکسادولین

⚠ Unverified

🍽️ Alimentary Tract And MetabolismGut mu/kappa opioid agonist (antidiarrhoeal)

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA206940 ATC A07DA06

Market / country: 🇺🇸 USA

Viberzi (US)

🧮 Dose calculator

Disease / regimen

Functional bowel / irritable bowel syndrome · Regimen source: FDA Viberzi · 2

• 75 mg twice daily: intolerance of 100 mg, OATP1B1 inhibitors, mild/moderate hepatic impairment, eGFR <60, or ESRD not on dialysis. Stop if severe constipation. FDA Viberzi · 2

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ No gallbladder; biliary duct obstruction or sphincter of Oddi disease; alcoholism or >3 alcoholic drinks a day; history of pancreatitis or structural pancreatic disease; severe hepatic impairment; history of severe constipation or mechanical bowel obstruction; hypersensitivity. FDA Viberzi · 4

Warnings

• Pancreatitis; sphincter of Oddi spasm; hypersensitivity; constipation. FDA Viberzi · 5

Renal adjustment

• eGFR < 60: eGFR <60 (and ESRD not on dialysis): 75 mg twice daily. FDA Viberzi · 2

Formulations

100 mg tablet — tablet 🇺🇸 USA FDA Viberzi · 3
75 mg tablet — tablet 🇺🇸 USA FDA Viberzi · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Viberzi · 8.1
“Risk Summary There are no studies with VIBERZI in pregnant women that inform any drug-associated risks.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Viberzi · 8.2
“Risk Summary No data are available regarding the presence of eluxadoline in human milk, the effects of eluxadoline on the breastfed infant, or the effects of eluxadoline on milk production.”
👶 ChildrenNo data
The source for this drug has no section for this group.
👴 Older adultsNo data
The source for this drug has no section for this group.
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA206940
DailyMed (FDA label)FDA Viberzi
MedlinePlus (NIH)Eluxadoline
WHO ATC/DDDA07DA06
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Viberzi · 3 FDA Viberzi · 2 FDA Viberzi · 4 FDA Viberzi · 5 FDA Viberzi · SPL approval / marketing category FDA Viberzi · 8.1 FDA Viberzi · 8.2
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Alosetron Chlordiazepoxide/clidinium Dicyclomine Hyoscine butylbromide Linaclotide Lubiprostone Mebeverine Plecanatide Rifaximin